Digest Network How does it work
Network
/
Society
Ce
Not verified

Celltrion

What we write about

BiotechnologyHealthIndustriaMedicine - variousPharmaceuticals

20 Press releases

View all press releases
27/11/2025
Industria
Scienza
Medicine - various
Biotechnology
Sanità
Health
Pharmaceuticals
Oncology
Celltrion receives Health Canada approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg)
Source
Celltrion
Issuer
Business Wire
1.00
0
08/10/2025
Health
Scienza
Medicine - various
Pharmaceuticals
Biotechnology
Market analysis
Celltrion presenta dati dal mondo reale positivi sullo switch da somministrazione endovenosa (EV) a sottocutanea (SC) di infliximab alle sessioni Meet the Expert della UEG Week 2025
Source
Celltrion
Issuer
Business Wire
1.00
0
06/10/2025
Health
Scienza
Medicine - various
Pharmaceuticals
Biotechnology
Market analysis
Celltrion Presents Positive Real-World Data on Switching from intravenous (IV) to subcutaneous (SC) infliximab at UEG Week 2025 Meet the Expert sessions
Source
Celltrion
Issuer
Business Wire
1.00
0
19/09/2025
Scienza
Medicine - various
Sanità
Biotechnology
Pharmaceuticals
Health
Oncology
Industria
Health Canada approves Celltrion’s Stoboclo® and Osenvelt®(CT-P41), denosumab biosimilars for the treatment of all indications approved for the reference products, Prolia® and Xgeva®, respectively
Source
Celltrion
Issuer
Business Wire
1.00
0
18/09/2025
Health
Scienza
Medicine - various
Pharmaceuticals
Biotechnology
Eventi
Fairs
Celltrion annuncia la disponibilità commerciale di Omlyclo™ in tutta Europa al congresso EADV 2025
Source
Celltrion
Issuer
Business Wire
1.00
0
18/09/2025
Health
Scienza
Medicine - various
Pharmaceuticals
Biotechnology
Eventi
Fairs
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 2025
Source
Celltrion
Issuer
Business Wire
1.00
0
25/02/2025
Scienza
Biotechnology
Pharmaceuticals
Optics
Sanità
Health
Medicine - various
Industria
Celltrion espande il portfolio di biosimilari nell'Unione europea in seguito all'approvazione di due biosimilari da parte della Commissione europea
Source
Celltrion
Issuer
Business Wire
1.00
0
25/02/2025
Scienza
Marketing
Communication
Medicine - various
Biotechnology
Sanità
Health
Pharmaceuticals
Industria
Celltrion riceve l'autorizzazione della CE per Avtozma® (CT-P47), un farmaco biosimilare di RoActemra® (tocilizumab)
Source
Celltrion
Issuer
Business Wire
1.00
0
23/02/2025
Scienza
Marketing
Communication
Medicine - various
Biotechnology
Sanità
Health
Pharmaceuticals
Industria
Celltrion Receives EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra® (tocilizumab)
Source
Celltrion
Issuer
Business Wire
1.00
0
20/02/2025
Eventi
Industria
Biotechnology
Sanità
Health
Pharmaceuticals
Medicine - various
Celltrion Unveils New Post-Hoc Analyses of LIBERTY Studies at the 20th ECCO Congress Further Evaluating the Efficacy and Safety of Subcutaneous (SC) Infliximab
Source
Celltrion
Issuer
Business Wire
1.00
0

Contact details

Social Media

Followers
0
Compatibility
0